Meeting
2024 ASCO Genitourinary Cancers Symposium
Cost-effectiveness-analysis of different treatment modalities in bacillus Calmette-Guérin (BCG) unresponsive non-muscle invasive bladder cancer (NIMBC).
Authors
Constantin Rieger
Department of Urology, University Hospital Cologne, Cologne, Germany
Constantin Rieger , Joerg Schluechtermann , Enno Storz , David A. Pfister , Axel Heidenreich
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 556)
DOI
10.1200/JCO.2024.42.4_suppl.556
Abstract #
556
Poster Bd #
E5
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition (ICI) versus cisplatin-based chemotherapy (CBC) in muscle-invasive bladder cancer (MIBC).
First Author: Ali Raza Khaki
Poster
2024 ASCO Genitourinary Cancers Symposium
Population based trends in intravesical gemcitabine use among patients with high-risk non-muscle invasive bladder cancer.
First Author: Stephen B. Williams
Poster
2024 ASCO Genitourinary Cancers Symposium
Cost-effectiveness of triplet therapies in metastatic hormone-sensitive prostate cancer used in PEACE-1 and ARASENS.
First Author: Nataniel Hernan Lester-Coll
Poster
2023 ASCO Genitourinary Cancers Symposium
Intravesical gemcitabine and docetaxel in the treatment of BCG-naïve non–muscle invasive urothelial carcinoma of the bladder: Updates from a phase 2 trial.
First Author: Sunil H. Patel